Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−4.50EUR
−6.79 MEUR
9.18 MEUR
1.53 M
About MARINOMED BIOTECH AG
Sector
CEO
Andreas Grassauer
Headquarters
Korneuburg
Website
Employees (FY)
52
Founded
2006
FIGI
BBG00MKMQ109
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MARI is 17.50 EUR — it has decreased by 2.78% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange MARINOMED BIOTECH AG stocks are traded under the ticker MARI.
MARINOMED BIOTECH AG is going to release the next earnings report on May 22, 2024. Keep track of upcoming events with our Earnings Calendar.
MARI stock is 9.09% volatile and has beta coefficient of 0.49. Check out the list of the most volatile stocks — is MARINOMED BIOTECH AG there?
MARINOMED BIOTECH AG revenue for the last quarter amounts to 751.00 K EUR despite the estimated figure of 750.00 K EUR. In the next quarter revenue is expected to reach 1.70 M EUR.
Yes, you can track MARINOMED BIOTECH AG financials in yearly and quarterly reports right on TradingView.
MARI stock has fallen by 12.06% compared to the previous week, the month change is a 16.27% fall, over the last year MARINOMED BIOTECH AG has showed a 50.00% decrease.
MARI net income for the last quarter is −1.19 M EUR, while the quarter before that showed −2.09 M EUR of net income which accounts for 43.06% change. Track more MARINOMED BIOTECH AG financial stats to get the full picture.
Today MARINOMED BIOTECH AG has the market capitalization of 26.96 M, it has decreased by 1.81% over the last week.
No, MARI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MARI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MARINOMED BIOTECH AG stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 52.00 employees. See our rating of the largest employees — is MARINOMED BIOTECH AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MARINOMED BIOTECH AG technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MARINOMED BIOTECH AG stock shows the sell signal. See more of MARINOMED BIOTECH AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MARINOMED BIOTECH AG future price: according to them, MARI price has a max estimate of 19.50 EUR and a min estimate of 19.50 EUR. Read a more detailed MARINOMED BIOTECH AG forecast: see what analysts think of MARINOMED BIOTECH AG and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MARINOMED BIOTECH AG EBITDA is −4.45 M EUR, and current EBITDA margin is −63.40%. See more stats in MARINOMED BIOTECH AG financial statements.